Chippenham-based drug development firm Ventura, has entered into a global development and licence agreement with leading American bio-tech company Janssen Biotech.
The deal will allow for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/ chronic obstructive pulmonary disease (COPD).
The collaboration will leverage Vectura’s expertise and proprietary dry powder inhaler technologies in the development of inhaled therapeutics. Vectura will apply its delivery technologies to develop Janssen’s pulmonary products into late-stage clinical development and commercialisation.
Janssen will lead the clinical development programmes, with Vectura taking responsibility for pharmaceutical development and preparation for Phase II clinical trials.
Financial terms of the agreement have not been disclosed, but the company has announced that the deal comprises upfront and development milestones and a tiered royalty on net sales.
Dr. Chris Blackwell, Chief Executive of Vectura, commented: “Vectura’s role in this agreement is to apply its expertise in the development of products for airway-related diseases and to utilise its technology/device platform offerings, some of which have regulatory and commercial validation. Vectura continues to be viewed as a partner of choice by companies seeking to address the unmet medical needs of patients with airway diseases.”
Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company.